SBM Sirona Biochem Corp.

Sirona Biochem Engages Global Beauty Consulting

Sirona Biochem Engages Global Beauty Consulting

VANCOUVER, British Columbia, Feb. 15, 2024 (GLOBE NEWSWIRE) -- (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory (GBC), under the leadership of CEO Gaël Boutry, a distinguished French formulator. GBC is currently developing an exclusive premium formulation for GlycoProteMimTM in anticipation of its launch in the first quarter of 2025.

GBC has a history of working with Sirona Biochem on the formulation of TFC-1067 for clinical development. This new venture is pivotal in building a brand and competitive product line that showcases GlycoProteMim's potent anti-aging benefits through its exclusive distribution brand Sirona LaboratoriesTM.

CEO Gaël Boutry has embraced the task of developing an unparalleled formula aimed at meeting the exacting demands of discerning cosmetic customers. “Our expertise teaches us that superior formulation is essential for securing a dedicated, repeat customer base for a new brand. We are in the process of creating a bespoke formula for GlycoProteMim, which we believe will lay the groundwork for forthcoming skincare offerings featuring GlycoProteMim”, reports Mr. Boutry.

Dr. Geraldine Deliencourt, Chief Scientific Officer at Sirona Biochem, stated, "With more than two decades of expertise and enriched by French craftsmanship, we are excited to utilize their meticulous service and attention to detail for the formulation of our first among many anticipated commercial products we plan to launch in Sirona Laboratories."

About Sirona Biochem Corp.

Sirona is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit .

About Global Beauty Consulting

Global Beauty Consulting offers a complete service in the cosmetics industry. We handle all aspects of your project through formulation, regulation, GMP implementation and assistance in the establishment of plants and laboratories. For more information, please visit or

For more information regarding this press release, please contact:

Investor Enquiries:

Email:

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.



EN
15/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sirona Biochem Corp.

 PRESS RELEASE

Sirona Biochem Announces Debenture Financing

Sirona Biochem Announces Debenture Financing VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures (the “Convertible Debentures”). The Convertible Debentures will be offered in units (the “Debenture Units”) at a price of $1,000 per Debenture Unit for aggregate gross proceeds of up to $400,000 (the “Offering”). The Company plans to use the proceeds of the Offering for general corporate purposes. Each Debenture Un...

 PRESS RELEASE

Sirona Biochem Secures Strategic Investment Agreements and New Joint V...

Sirona Biochem Secures Strategic Investment Agreements and New Joint Venture with Promura GmbH VANCOUVER, British Columbia, April 22, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”), a biotechnology company specializing cosmetic ingredients and new drug discoveries, is pleased to announce the successful execution of a strategic investment agreement with Promura GmbH, a German-based investor. The agreement includes the private placement of $3 million CAD in unsecured, 12% convertible debentures, by Promura GmbH. In addition to the convertible ...

 PRESS RELEASE

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark R...

Sirona Biochem Showcases TFC-1326 in Stonegate Healthcare’s Landmark Report VANCOUVER, British Columbia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is excited to announce that its cutting-edge anti-aging compound, TFC-1326, has been highlighted in Stonegate Healthcare Partners’ latest research report. The publication, titled "Sirona Biochem’s TFC-1326 Clinical Data Versus Retinoid Clinical Data," provides an extensive evaluation of TFC-1326’s clinical trial performance, setting it apart from traditional retinoid treatments. The report outl...

 PRESS RELEASE

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-13...

Sirona Biochem Announces Publication of Groundbreaking Study on TFC-1326 Compound in the Journal of Cosmetic Dermatology VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) is proud to announce the publication of a pivotal research article in the prestigious Journal of Cosmetic Dermatology. About the Study The article, titled “TFC-1326 Compound Reduces Clinical Signs of Skin Aging: Evidence From In Vitro Human Adipose and Skin Models and Pilot Clinical Trial,” highlights the groundbreaking efficacy of Sirona’s proprietary compound ...

 PRESS RELEASE

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Produc...

SIRONA BIOCHEM Poised for Profitability in 2025 with Anti-Aging Product Rollout VANCOUVER, British Columbia, Sept. 25, 2024 (GLOBE NEWSWIRE) -- . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear Shareholders, We are thrilled to provide an update on our efforts to bring our innovative cosmeceutical portfolio to global markets, with the initial launch set for early 2025. The commercialization of our first cosmetic product, a serum containing our GlycoProteMim™ active is progressing smoothly, in line with the timeline outlined in o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch